110 related articles for article (PubMed ID: 15172047)
1. Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis.
Kremer JM
Rheum Dis Clin North Am; 2004 May; 30(2):381-91, viii. PubMed ID: 15172047
[TBL] [Abstract][Full Text] [Related]
2. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.
Scheinfeld N
J Dermatolog Treat; 2006; 17(4):229-34. PubMed ID: 16971318
[TBL] [Abstract][Full Text] [Related]
3. [Fusion protein abatacept. Remission in every 5th TNF-alpha refractory patient].
MMW Fortschr Med; 2008 Jun; 150(26-27):56-7. PubMed ID: 18683309
[No Abstract] [Full Text] [Related]
4. T-cell agents in the treatment of rheumatoid arthritis.
Solomon GE
Bull NYU Hosp Jt Dis; 2010; 68(3):162-5. PubMed ID: 20969545
[TBL] [Abstract][Full Text] [Related]
5. [CTLA4-Ig (abatacept)].
Harigai M
Nihon Rinsho; 2007 Jul; 65(7):1231-7. PubMed ID: 17642237
[TBL] [Abstract][Full Text] [Related]
6. Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation.
Konsta M; Rallis E; Karameris A; Stratigos A; Sfikakis PP; Iliopoulos A
J Eur Acad Dermatol Venereol; 2012 Feb; 26(2):257-8. PubMed ID: 22280512
[No Abstract] [Full Text] [Related]
7. Abatacept mechanism of action: concordance with its clinical profile.
Herrero-Beaumont G; Martínez Calatrava MJ; Castañeda S
Reumatol Clin; 2012; 8(2):78-83. PubMed ID: 22104048
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic T lymphocyte-associated antigen 4 Ig-induced asthma in the treatment of rheumatoid arthritis.
Bao J; Li T; Zhao J; Zhang CY
J Rheumatol; 2012 Sep; 39(9):1903. PubMed ID: 22942310
[No Abstract] [Full Text] [Related]
9. [Pharmacological properties and clinical efficacy of abatacept (Orencia(®)) for the treatment of rheumatoid arthritis].
Yasuoka Y; Goto A; Seriu T
Nihon Yakurigaku Zasshi; 2011 Feb; 137(2):87-94. PubMed ID: 21321458
[No Abstract] [Full Text] [Related]
10. Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis.
Amezcua-Guerra LM; Hernández-Martínez B; Pineda C; Bojalil R
Gut; 2006 Jul; 55(7):1059-60. PubMed ID: 16766771
[No Abstract] [Full Text] [Related]
11. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
Ruderman EM; Pope RM
Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145
[TBL] [Abstract][Full Text] [Related]
12. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
Manadan AM; Block JA
Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of abatacept in patients with rheumatoid arthritis and no prior treatment with biologics].
Escudero Contreras A; Castro-Villegas MC; Hernández-Hernández MV; Díaz-González F
Reumatol Clin; 2011; 7(6):392-6. PubMed ID: 22078698
[TBL] [Abstract][Full Text] [Related]
14. CTLA4Ig and the therapeutic potential of T cell co-stimulation blockade.
Graca L
Acta Reumatol Port; 2008; 33(3):267-76. PubMed ID: 18846007
[TBL] [Abstract][Full Text] [Related]
15. T-cell agents in the treatment of rheumatoid arthritis - 2011 update.
Solomon GE
Bull NYU Hosp Jt Dis; 2011; 69(3):230-2. PubMed ID: 22035434
[No Abstract] [Full Text] [Related]
16. Reduced numbers of circulating CD28-negative CD4+ cells in patients with rheumatoid arthritis chronically treated with abatacept.
Gómez-García L; Ramírez-Assad C; Vargas A; Massó F; Sánchez-Muñoz F; Márquez-Velasco R; Amezcua-Guerra LM; Bojalil R
Int J Rheum Dis; 2013 Aug; 16(4):469-71. PubMed ID: 23992270
[No Abstract] [Full Text] [Related]
17. [Abatacept in the treatment of active rheumatoid arthritis].
Nielsen H; Hansen A
Ugeskr Laeger; 2009 Jan; 171(4):214-7. PubMed ID: 19174034
[TBL] [Abstract][Full Text] [Related]
18. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.
Korhonen R; Moilanen E
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):276-84. PubMed ID: 19228144
[TBL] [Abstract][Full Text] [Related]
19. T-cell agents in the treatment of rheumatoid arthritis - 2012 update.
Solomon GE
Bull NYU Hosp Jt Dis; 2012; 70(3):191-4. PubMed ID: 23259627
[No Abstract] [Full Text] [Related]
20. COBRA combination therapy in daily practice--getting back to the future.
Boers M
Rheumatology (Oxford); 2008 Jan; 47(1):1-2. PubMed ID: 18077485
[No Abstract] [Full Text] [Related]
[Next] [New Search]
